Background: Allergic rhinitis involves inflammation of the nasal passages. The use of nasal steroids is generally very effective in providing significant symptom relief. However, compliance for their use is sometimes poor. Methods: To examine the efficacy of early intervention (before pollen dispersal) with oral cysteinyl leukotriene receptor antagonists (LTRA) on pollinosis in patients with allergy to cedar and Japanese cypress pollens, groups of subjects were treated with LTRA or a placebo for 4 weeks at the beginning of the cedar pollen dispersal season. Subsequently, all patients received nasal steroid therapy concomitantly with LTRA throughout the remaining period of the pollen dispersal season. The effects of such early treatment with LTRA on pollinosis were investigated using symptom scores from an allergy diary and quality of life (QOL) scores. Results: Sneezing and nasal congestion scores were significantly lower in the LTRA-pretreated subjects than observed in the placebo-pretreated patients between weeks 4 and 6 and weeks 3 and 5, respectively. QOL scores improved significantly in all domains after concomitant therapy with nasal steroids. The percent improvement in the nasal congestion score after the concomitant therapy was significantly higher in the LTRA group (69%) than in the placebo group (41%). Conclusion: Significant differences observed in symptoms and in QOL effects between LTRA- and placebo-pretreated patients and the absence of major adverse effects noted in these studies suggest that early intervention with LTRA is beneficial and safe and should be considered in the management of pollinosis-associated allergic rhinitis.

Keywords:
Pollinosis, Cedar pollen, Cypress pollen, Leukotriene receptor antagonist
1.
Barnes PJ: New directions in allergic diseases: mechanism-based anti-inflammatory therapies. J Allergy Clin Immunol 2000;106:5–16.
2.
Bousquet J, Van Cauwenberge P, Khaltaev N, Aria Workshop Group, World Health Organization: Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:s220–s251.
3.
Okuda M: Epidemiology of Japanese cedar pollinosis throughout Japan. Ann Allergy Asthma Immunol 2003;91:288–296.
4.
Practical Guideline for the Management of Allergic Rhinitis in Japan – Perennial Rhinitis and Pollinosis, ed 5. Tokyo, Life Science, 2005.
5.
Kaneko Y, Motohashi Y, Nakamura H, Endo T, Eboshida A: Increasing prevalence of Japanese cedar pollinosis: a meta-regression analysis. Int Arch Allergy Immunol 2005;136:365–371.
6.
Ito H, Nishimura J, Suzuki M, Mamiya S, Sato K, Takagi I, Baba S: Specific IgE to Japanese cypress (Chamaecyparis obtusa) in patients with nasal allergy. Ann Allergy Asthma Immunol 1995;74:299–303.
7.
Lipworth BJ: Emerging role of antileukotriene therapy in allergic rhinitis. Clin Exp Allergy 2001;31:1813–1821.
8.
Meltzer EO: Clinical evidence for antileukotriene therapy in the management of allergic rhinitis. Ann Allergy Asthma Immunol 2002;88:23–29.
9.
Peters-Golden M, Gleason MM, Togias A: Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis. Clin Exp Allergy 2006;36:689–703.
10.
Fukushima C, Matsuse H, Hishikawa Y, Kondo Y, Machida I, Saeki S, Kawano T, Tomari S, Obase Y, Shimoda T, Kohono S: Pranlukast, a leukotriene receptor antagonist, inhibits interleukin-5 production via a mechanism distinct from leukotriene receptor antagonism. Int Arch Allergy Immunol 2005;136:165–172.
11.
Wilson AM, O’Byrne PM, Parameswaran K: Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 2004;116:338–344.
12.
Meltzer EO, Malmstrom K, Lu S, Prenner BM, Wei LX, Weinstein SF, Wolfe JD, Reiss TF: Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 2000;105:917–922.
13.
Barnes NC, de Jong B, Miyamoto T: Worldwide clinical experience with the first marketed leukotriene receptor antagonist. Chest 1997;111:s52–s60.
14.
Borres MP, Brakenhielm G, Irander K: How many teenagers think they have allergic rhinoconjunctivitis and what they do about it. Ann Allergy Asthma Immunol 1997;78:29–34.
15.
Okuda M, Ohkubo K, Gotoh M, Ishida Y: Treatment of Japanese cedar pollinosis and its impact on patient satisfaction. Arerugi 2004;53:596–600.
16.
Kaliner MA: Patient preferences and satisfaction with prescribed nasal steroids for allergic rhinitis. Allergy Asthma Proc 2001;22:s11–s15.
17.
Konno A, Yamagoshi T, Usui S: Clinical assessment of ONO-1078 (pranlukast hydrate) against perennial allergic rhinitis – clinical pharmacological study using airway resistance in the nasal cavity as an indicator – (a double-blind comparative study using placebo as a control drug). J Clin Ther Med 1997;13:1921–1939.
18.
Okubo K, Gotoh M, Shimada K, Ristu M, Kobayashi M, Okuda M: Effect of fexofenadine on the quality of life of Japanese cedar pollinosis patients. Allergol Int 2004;53:245–254.
19.
Okubo K, Gotoh M, Shimada K, Ritsu M, Okuda M, Crawford B: Fexofenadine improves the quality of life and work productivity in Japanese patients with seasonal allergic rhinitis during the peak cedar pollinosis season. Int Arch Allergy Immunol 2005;136:148–154.
20.
Okuda M: Grading the severity of allergic rhinitis for treatment strategy and drug study purposes. Curr Allergy Asthma Rep 2001;1:235–241.
21.
Noonan MJ, Raphael GD, Nayak A, Greos L, Olufade AO, Leidy NK, Champan D, Kramer B: The health-related quality of life effects of once-daily cetirizine HCl in patients with seasonal allergic rhinitis: a randomized double-blind, placebo-controlled trial. Clin Exp Allergy 2003;33:351–358.
22.
Kremer B, Klimek L, Bullinger M, Mösges R: Generic or disease-specific quality of life scales to characterize health status in allergic rhinitis? Allergy 2001;56:957–963.
23.
Thompson AK, Juniper E, Meltzer EO: Quality of life in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2000;85:338–348.
24.
Delaunay JJ, Sasajima H, Okamoto Y, Yokota M: Side-by-side comparison of automatic pollen counters for use in pollen information systems. Ann Allergy Asthma Immunol 2007;98:553–558.
25.
Holgate ST, Peters-Golden M, Panettieri RA, Henderson WR Jr: Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J Allergy Clin Immunol 2003;111:s18–s36.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.